136 related articles for article (PubMed ID: 9706433)
1. Prolactin modulates the disease activity of systemic lupus erythematosus accompanied by prolactinoma.
Funauchi M; Ikoma S; Enomoto H; Sugiyama M; Ohno M; Hamada K; Kanamaru A
Clin Exp Rheumatol; 1998; 16(4):479-82. PubMed ID: 9706433
[TBL] [Abstract][Full Text] [Related]
2. First reported pediatric case of systemic lupus erythematosus associated with prolactinoma.
Reuman PD
Arthritis Rheum; 2004 Nov; 50(11):3616-8. PubMed ID: 15529390
[TBL] [Abstract][Full Text] [Related]
3. Prolactin has a pathogenic role in systemic lupus erythematosus.
Jara LJ; Medina G; Saavedra MA; Vera-Lastra O; Torres-Aguilar H; Navarro C; Vazquez Del Mercado M; Espinoza LR
Immunol Res; 2017 Apr; 65(2):512-523. PubMed ID: 28130617
[TBL] [Abstract][Full Text] [Related]
4. An SLE patient with prolactinoma and recurrent granulomatous mastitis successfully treated with hydroxychloroquine and bromocriptine.
Zhang LN; Shi TY; Yang YJ; Zhang FC
Lupus; 2014 Apr; 23(4):417-20. PubMed ID: 24446305
[TBL] [Abstract][Full Text] [Related]
5. Normal growth and pubertal development during bromocriptine therapy in two patients with prolactinoma.
Kamel N; Uysal AR; Cesur V; Erdoğan G; Başkal N
Endocr J; 1995 Aug; 42(4):581-6. PubMed ID: 8556068
[TBL] [Abstract][Full Text] [Related]
6. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus.
Walker SE; McMurray RW; Houri JM; Allen SH; Keisler D; Sharp GC; Schlechte JA
Ann N Y Acad Sci; 1998 May; 840():762-72. PubMed ID: 9629303
[TBL] [Abstract][Full Text] [Related]
7. Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes.
Oshige T; Nakamura Y; Sasaki Y; Kawano S; Ohki T; Tsuruta M; Tokubuchi I; Nakayama H; Yamada K; Ashida K; Tajiri Y; Nomura M
Intern Med; 2019 Nov; 58(21):3125-3128. PubMed ID: 31243214
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
9. A case of large prolactinoma supposed to be cured by bromocriptine therapy.
Arita K; Uozumi T; Ohta M
Endocrinol Jpn; 1988 Jun; 35(3):503-9. PubMed ID: 3197661
[TBL] [Abstract][Full Text] [Related]
10. Increased serum level of prolactin is related to autoantibody production in systemic lupus erythematosus.
Yang J; Li Q; Yang X; Li M
Lupus; 2016 Apr; 25(5):513-9. PubMed ID: 26678441
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
van der Lely AJ; Brownell J; Lamberts SW
J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
[TBL] [Abstract][Full Text] [Related]
12. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
Kupersmith MJ; Kleinberg D; Warren FA; Budzilovitch G; Cooper P
Neurosurgery; 1989 Mar; 24(3):417-23. PubMed ID: 2927618
[TBL] [Abstract][Full Text] [Related]
13. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
Tyson D; Reggiardo D; Sklar C; David R
Am J Dis Child; 1993 Oct; 147(10):1057-61. PubMed ID: 8213676
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of prolactinomas.
Molitch ME
Adv Intern Med; 1999; 44():117-53. PubMed ID: 9929707
[No Abstract] [Full Text] [Related]
15. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus.
McMurray RW; Weidensaul D; Allen SH; Walker SE
J Rheumatol; 1995 Nov; 22(11):2084-91. PubMed ID: 8596149
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases.
Neidhart M
J Rheumatol; 1996 Mar; 23(3):476-81. PubMed ID: 8832986
[TBL] [Abstract][Full Text] [Related]
18. [Macroprolactinoma resistant to bromocriptine].
López-Espinosa E; Ayala AR; Grimaldo J; Kunhardt J; Villanueva C
Arch Invest Med (Mex); 1989; 20(1):1-8. PubMed ID: 2669670
[TBL] [Abstract][Full Text] [Related]
19. The long-term effects of pregnancy and bromocriptine treatment on prolactinomas--the value of radiologic studies.
Badawy SZ; Marziale JC; Rosenbaum AE; Chang JK; Joy SE
Early Pregnancy; 1997 Dec; 3(4):306-11. PubMed ID: 10086082
[TBL] [Abstract][Full Text] [Related]
20. Increased plasma VIP concentration in patients with prolactinoma.
Makowska A; Zgliczyński W; Słowińska-Srzednicka J; Soszyński P; Zgliczyński S
Endokrynol Pol; 1992; 43(3):230-3. PubMed ID: 1345563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
